While most RSV infections go away in a week or two, they can also cause more serious health problems, such as lung infections, and lead to hospitalizations. Amongadults over 65, RSV is responsible for 60,000 to 120,000 hospitalizations and 6,000 to 10,000 deaths each year. I...
RSV leads to mild illness in most people but can cause severe illness in some young children and older adults. The CDC says older adults aged 65 and above are at high risk for severe infection from RSV, particularly those with chronic lung or heart conditions and weakened immune systems. ...
In older adults, declining immune function and a higher burden of pulmonary or circulatory conditions make RSV dangerous. Falsey says, “Initially, it’s a very snotty, wheezy, phlegmy virus.” It begins as a cold but can worsen after a few days; patients’ airways can become inflamed and ...
As of Oct. 5, theCDC reportedthat 37% of people 75 and older say they have ever received an RSV vaccine, and 13% said they will definitely get one. Among adults 60 to 74 years old, 24% said they’d been vaccinated for RSV, and 10% said they definitely will get the shot. Cases ...
For starters, it’s not yet known how often people will need to be re-vaccinated, though it is clear that for at least the GSK and Pfizer vaccines, annual vaccination is not needed. So any older adult who has already received an RSV shot isn’t eligible to get another at this time....
However, this season there will be protection against RSV offered to many Americans for the first time ever. Firstly,adults over 60 will be able to get vaccinated. Similar to flu shots, the vaccines will be available at major pharmacy chains such as CVS, Rite Aid and Walg...
23 The 16 million older adults in the United States without a Part D plan face out-of-pocket costs ranging from $180 to $295 per shot. RSV vaccines for patients aged 60 to 65 years who are not eligible for Medicare should have coverage by private insurance plans because they are ...
term future. The panel may also vote on a narrower age cutoff for the shot. In the CDC's February meeting, a majority of the agency's work group on the topic favored recommending GSK's vaccine for adults 65 and older but not for those as young as 60, the CDC's Michael Melgar said...
that is intended to provide partial immunity for newborns and babies up to 1 year old. Although similar to a vaccine in that it provides a level of immunity to those who receive the shot, this injection directly provides the antibodies to the babies rather than ramping up their immune ...
Both companies have asked the FDA to approve their RSV shot for adults ages 60 and older. The agency is expected to make its decision on GSK's vaccine by May 3 with Pfizer's answer expected to come that month as well. GSK's and Pfizer's respective vaccines stand to b...